News | June 03, 2021
Lupin announces U.S. FDA acceptance for pegfilgrastim biosimilar application
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
For undertaking production, the company has been provided a Rs. 65 crore grant by the centre and Rs. 94 crore from the government of Maharashtra
Aurobindo has one of the most enduring generics ecosystems among peers
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
7.94 crore doses were made available to the states in May 2021
Adjusted PAT declined 18.8% YoY
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from 28th May 2021
Subscribe To Our Newsletter & Stay Updated
